Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting

Jun 01, 2015, 02:34 ET from Hutchison China MediTech Limited

LONDON, June 1, 2015 /PRNewswire/ --

Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM), today announces that AstraZeneca AB (publ) ("AstraZeneca"), Hutchison MediPharma Limited's ("HMP") collaboration partner, presented preliminary data from the ongoing Phase Ib clinical trial of HMP's c-Met inhibitor savolitinib (AZD6094) combined with AstraZeneca's drug candidate AZD9291 in non-small cell lung cancer ("NSCLC").

AZD9291 is AstraZeneca's investigational inhibitor of the epidermal growth factor receptor (EGFR). Preliminary data on the activity of AZD9291 in patients with EGFR mutation positive NSCLC who had failed currently-approved EGFR tyrosine kinase inhibitors was presented at the American Society of Clinical Oncology (ASCO) meeting in June 2014. In mid-2014 AstraZeneca commenced the TATTON study, a multi-arm Phase Ib study of AZD9291 in combination with either savolitinib (AZD6094) (c-MET inhibitor), MEDI4736 (anti-PD-L1 mAb) or selumetinib (MEK1/2 inhibitor) in EGFR mutation positive NSCLC. For those patients who received AZD9291 and savolitinib, the primary objective of the TATTON study was to establish a safe and effective combination dose.  All patients were screened for their T790M status (+/-) as well as some, if sufficient tissue samples were available, for their c-Met (+/-) status.

The following poster was presented at the American Society of Clinical Oncology annual meeting in Chicago on 30 May 2015.


   
    Title:       Preliminary results of TATTON, a multi-arm phase Ib trial
                 of AZD9291 combined with MEDI4736, AZD6094 or selumetinib
                 in EGFR-mutant lung cancer.
    Authors:     Oxnard G.R., et al.
    Abstract:    #2509 - available at abstracts.asco.org/156/AbstView_156_148945.html
    Session:     Developmental Therapeutics - Clinical Pharmacology and Experimental
                 Therapeutics
    Date & Time: Saturday 30 May 8:00 AM-11:30 AM

A total of 12 patients were dosed with either 600mg or 800mg daily doses of savolitinib (AZD6094) in combination with 80mg (once daily) AZD9291.  In terms of the primary aims of the study, the 600mg combination dose was well tolerated with toxicity profiles that allow for combination at doses previously demonstrated to be biologically active.  Of the 11 evaluable patients in the study, 6 partial responses (confirmed and unconfirmed) have been observed to date. Responses to date include 4 of 7 patients with confirmed T790M negative status.

The presentation will be made available at http://chi-med.com/eng/irinfo/presentations.htm.  

Christian Hogg, Chief Executive Officer of Chi-Med said: "Savolitinib is a highly selective c-Met inhibitor designed to eliminate the toxicities experienced by the first wave of c-Met inhibitors in their early development. We are now very pleased to see encouraging early efficacy data emerge in non-small cell lung cancer to add to the efficacy already reported in papillary renal cell carcinoma and colorectal cancer."  

About Chi-Med 

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited.  For more information, please visit: chi-med.com.

Enquiries

Chi-Med
Christian Hogg
CEO
Telephone: +852-2121-8200
   
Panmure Gordon (UK) Limited
Richard Gray
Andrew Potts
Telephone: +44-20-7886-2500
   
Citigate Dewe Rogerson
Anthony Carlisle
David Dible
Telephone: +44-20-7638-9571
Mobile: +44-7973-611-888
Mobile: +44-7967-566-919
Email: David.Dible@citigatedr.co.uk

SOURCE Hutchison China MediTech Limited